Skip to content

Our Company

About our company

We believe that the best source of new treatments comes from identifying, shaping and strengthening early drug innovation. We want to challenge and apply science in combination with creativity and entrepreneurship to maximize health care value for society.

We seek ideas that could potentially both improve patient quality of life and streamline health care. Aqilion pursues and transforms ideas aimed at testing and refining science into clinical translation. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and take the product to the patients.

AQILION AB (publ) is a Swedish public limited company with the headquarters in Helsingborg, and an affiliate office in Medicon Village, Lund, in Sweden.

About our business

We explore ideas that are based on solid scientific grounds and that have the potential to become new medications and refines them into commercially interesting projects. It is becoming increasingly common for our customers, who represent the next step in the chain (the pharmaceutical and biotech industry) to acquire external development projects, and when they do so early in the development process. Thus, the innovative aspect combined with medical need are crucial factors.

We focus on indications within chronic inflammation and dysfunctional immunological reactions such as autoimmunity, where we see a great future need, good potential for innovation and a clear interest in the market.

About our company name

In 2019, the company name was changed to AQILION AB. The name symbolizes an astute and versatile organization that can apply the keen sight and precision of the eagle to find the early life science ideas that are a perfect fit for the Aqilion business model.

Aqilion derives from Aquila, the Latin name of a genus that includes eagles. Aquila is also the name of a constellation that is visible in the northern hemisphere. Our pipeline contains three in-house pharmaceutical development programs; Regulus, Alnitak and Polaris. All three were named for brightly shining stars, in analogy to the company’s name.

The Annual General Meeting 2020 decided to change the form of business, at which point the company became a public limited company, AQILION AB (publ).

When the company was founded back in 2002, the company name was Partners for Development Investments in Life Sciences, P.U.L.S. AB and was usually called PULS.